Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...
During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...
The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...
In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.
Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic ...
The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...
The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback